Literature DB >> 28926118

C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice.

Runping Liu1,2, Xiaojiaoyang Li1,2, Zhiming Huang3, Derrick Zhao1, Bhagyalaxmi Sukka Ganesh1, Guanhua Lai4, William M Pandak2,5, Phillip B Hylemon1,2,5, Jasmohan S Bajaj2,5, Arun J Sanyal5, Huiping Zhou1,2,3,5.   

Abstract

Impaired intestinal barrier function promotes the progression of various liver diseases, including cholestatic liver diseases. The close association of primary sclerosing cholangitis (PSC) with inflammatory bowel disease highlights the importance of the gut-liver axis. It has been reported that bile duct ligation (BDL)-induced liver fibrosis is significantly reduced in C/EBP homologous protein knockout (CHOP-/- ) mice. However, the underlying mechanisms remain unclear. In the current study, we demonstrate that BDL induces striking and acute hepatic endoplasmic reticulum (ER) stress responses after 1 day, which return to normal after 3 days. No significant hepatocyte apoptosis is detected 7-14 days following BDL. However, the inflammatory response is significantly increased after 7 days, which is similar to what we found in human PSC liver samples. BDL-induced loss of stemness in intestinal stem cells (ISCs), disruption of intestinal barrier function, bacterial translocation, activation of hepatic inflammation, M2 macrophage polarization and liver fibrosis are significantly reduced in CHOP-/- mice. In addition, intestinal organoids derived from CHOP-/- mice contain more and longer crypt structures than those from wild-type (WT) mice, which is consistent with the upregulation of stem cell markers (leucine-rich repeat-containing G-protein-coupled receptor 5, olfactomedin 4, and SRY [sex determining region Y]-box 9) and in vivo findings that CHOP-/- mice have longer villi and crypts as compared to WT mice. Similarly, mRNA levels of CD14, interleukin-1β, tumor necrosis factor-alpha, and monocyte chemotactic protein-1 are increased and stem cell proliferation is suppressed in the duodenum of patients with cirrhosis.
CONCLUSION: Activation of ER stress and subsequent loss of stemness of ISCs plays a critical role in BDL-induced systemic inflammation and cholestatic liver injury. Modulation of the ER stress response represents a potential therapeutic strategy for cholestatic liver diseases as well as other inflammatory diseases. (Hepatology 2018;67:1441-1457).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28926118      PMCID: PMC5859257          DOI: 10.1002/hep.29540

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

Review 1.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

2.  Endoplasmic reticulum stress and unfolded protein response in inflammatory bowel disease.

Authors:  Stewart S Cao
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

Review 3.  Alcoholic liver disease: mechanisms of injury and targeted treatment.

Authors:  Alexandre Louvet; Philippe Mathurin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

4.  The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.

Authors:  Yongqing Wang; Hiroaki Aoki; Jing Yang; Kesong Peng; Runping Liu; Xiaojiaoyang Li; Xiaoyan Qiang; Lixin Sun; Emily C Gurley; Guanhua Lai; Luyong Zhang; Guang Liang; Masayuki Nagahashi; Kazuaki Takabe; William M Pandak; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

Review 5.  Epithelial ER Stress in Crohn's Disease and Ulcerative Colitis.

Authors:  Stewart S Cao
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 6.  The Gut-Liver Axis in Primary Sclerosing Cholangitis.

Authors:  Bertus Eksteen
Journal:  Clin Liver Dis       Date:  2015-09-26       Impact factor: 6.126

7.  C/EBP homologous protein (CHOP) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver.

Authors:  Madhusudana R Chikka; Diane DeZwaan McCabe; Heather M Tyra; D Thomas Rutkowski
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

8.  HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

Authors:  Xudong Wu; Lixin Sun; Weibin Zha; Elaine Studer; Emily Gurley; Li Chen; Xuan Wang; Phillip B Hylemon; William M Pandak; Arun J Sanyal; Luyong Zhang; Guangji Wang; Jie Chen; Jian-Ying Wang; Huiping Zhou
Journal:  Gastroenterology       Date:  2009-09-02       Impact factor: 22.682

9.  Identification of stem cells in small intestine and colon by marker gene Lgr5.

Authors:  Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2007-10-14       Impact factor: 49.962

Review 10.  ER stress and hepatic lipid metabolism.

Authors:  Huiping Zhou; Runping Liu
Journal:  Front Genet       Date:  2014-05-09       Impact factor: 4.599

View more
  12 in total

Review 1.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 2.  Cellular Stress Responses and Gut Microbiota in Inflammatory Bowel Disease.

Authors:  Siyan Stewart Cao
Journal:  Gastroenterol Res Pract       Date:  2018-06-20       Impact factor: 2.260

3.  The possible association between AQP9 in the intestinal epithelium and acute liver injury‑induced intestinal epithelium damage.

Authors:  Tianxin Xiang; Shanfei Ge; Jiangxiong Wen; Junfeng Xie; Lixia Yang; Xiaoping Wu; Na Cheng
Journal:  Mol Med Rep       Date:  2018-10-10       Impact factor: 2.952

4.  Exogenous Therapeutics of Microrna-29a Attenuates Development of Hepatic Fibrosis in Cholestatic Animal Model through Regulation of Phosphoinositide 3-Kinase p85 Alpha.

Authors:  Ya-Ling Yang; Feng-Sheng Wang; Hung-Yu Lin; Ying-Hsien Huang
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

5.  E. coli NF73-1 Isolated From NASH Patients Aggravates NAFLD in Mice by Translocating Into the Liver and Stimulating M1 Polarization.

Authors:  Yifan Zhang; Weiwei Jiang; Jun Xu; Na Wu; Yang Wang; Tianyu Lin; Yun Liu; Yulan Liu
Journal:  Front Cell Infect Microbiol       Date:  2020-12-11       Impact factor: 5.293

6.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

7.  Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation.

Authors:  Runping Liu; Xiaojiaoyang Li; Phillip B Hylemon; Huiping Zhou
Journal:  Am J Pathol       Date:  2018-06-30       Impact factor: 5.770

Review 8.  Roles of the inflammasome in the gut‑liver axis (Review).

Authors:  Junfeng Wang; Rui Dong; Shan Zheng
Journal:  Mol Med Rep       Date:  2018-11-20       Impact factor: 2.952

9.  C/EBP Homologous Protein (CHOP) Activates Macrophages and Promotes Liver Fibrosis in Schistosoma japonicum-Infected Mice.

Authors:  Mengyun Duan; Yuan Yang; Shuang Peng; Xiaoqin Liu; Jixin Zhong; Yurong Guo; Min Lu; Hao Nie; Boxu Ren; Xiangzhi Zhang; Lian Liu
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

Review 10.  Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer.

Authors:  Xian-Yang Qin; Luc Gailhouste
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.